

Dengue Virus

CHARACTERISTICS

Svnonvm or Dengue fever, break bone fever, Dengue Cross Reference hemorrhagic fever (DHF) and Dengue shock

syndrome (DSS), DENV, DEN

Disease Dengue Virus Dengue hemorrhagic fever (DHF)

and Dengue shock syndrome (DSS)

Flaviviridae family, Flavivirus genus - arbovirus. Morphology

> 40-60 nm enveloped virus/isometric nucleocapsid 25-30 nm; ~10.7 kb, linear, positive-sense RNA genome. 4 serotypes (Dengue 1-4); genetically related to other flaviviruses (e.g., yellow fever,

tick-borne encephalitis).

Zoonosis Yes.via infected mosquitoes.

RISK GROUP & CONTAINMENT REQUIREMENTS

ABSL-2 For all procedures utilizing infected animals.

BSL-2/BSL-2+ For all procedures involving suspected or known

infectious specimen or cultures, work in a BSC unless otherwise approved and stated in lab-

specific manual.

Risk Group 2 Agents associated with human disease that

are rarely serious and often have preventive or

therapeutic interventions available.

LABORATORY HAZARDS

Primary Hazards Parenteral inoculation; bites from experimentally

infected mosquitoes - potentially infectious.

Sources Samples described in IBC protocol.

Lab Acquired There have been 14 reported cases of laboratory

Infections (LAIs) acquired infections with no deaths.

PERSONAL PROTECTIVE EQUIPMENT

Additional Additional PPE may be required depending on

Precautions lab-specific SOPs and IBC Protocol.

Minimum PPE Lab coat, disposable gloves, safety glasses, closed

Requirements toed shoes, long pants.

SPILL PROCEDURES

Large Immediately notify all lab personnel and clear the area.

Remove any contaminated PPE/clothing before exiting the lab. Lock all entry doors, post warning signage, and deny entry. Call DPS (213-740-4321) and ask to notify

EH&S. Inform the PI and/or Lab Manager/Supervisor.

Small Notify all lab personnel lab. Remove contaminated

> PPE and don new PPE. Cover spill area with absorbent material and add fresh 1:10 bleach:water. Allow 20 minutes (or as directed) contact time. After 20

minutes, clean up and dispose of materials.

VIABILITY

Disinfection Use 10 % dilution of household bleach (minimum

0.3% sodium hypochlorite) for 20 to 30 minutes, or an acceptable time approved by IBC and EH&S.

The virus is stable in dried blood for up to 9 weeks Survival Outside

Host at room temperature

HEALTH HAZARDS

Host Range Humans, Simians, and Mosquitoes

Incubation Average incubation period is 4-7 days (range of Period

3-15 days)

Infectious Dose Human ID50 is <10 PFU. Fewer than 10 PFU can

> lead to infection in 50% of volunteers treated with an attenuated dengue virus vaccine candidate.

Modes of Transmission

Transmitted to humans through mosquito bites or through contaminated blood transfusion.

Signs and Symptoms Influenza type symptoms, fever, rash, myalgias, arthralgias and febrile period lasting 2 to 10 days. Hemorrhagic fever risk is higher after secondary infection with other dengue serotypes. High fever, hemorrhagic diathesis, hepatomegaly, and shock are clinical manifestations of DHF and DSS. Hemorrhagic fever mortality rates up to 20%.

EXPOSURE PROCEDURES

Medical Follow-Visit USC's designated healthcare provider. Bring

a copy of this PSDS.

Mucous Flush eyes for 5-10 minutes at eyewash station.

Membrane

Other Exposures Immediately wash affected area with soap and

water for 15 minutes.

Reporting Immediately report incident to supervisor, notify

EH&S, and complete Manager's Report.

MEDICAL PRECAUTIONS/TREATMENT

Prophylaxis None

Surveillance Monitor for symptoms. Realtime PCR assay

measures RNA number as indicator of viral load. ELISA detects Dengue-induced seroconversion. Detection of NS1, NS2, NS3 and NS5 protein antibodies can aid in evaluating risk of DHF development. RT-PCR detects the virus directly.

Monitor patient's vital signs closely. Transfuse Treatment

plasma/blood in cases of severe hemorrhagic fever. Dextran 70 solns treat hemorrhagic shock.

to

LISC Immediately report any

exposures Requirements Environmental Health & Safety.

Vaccines No vaccine

REFERENCES

Canadian PSDS **BMBL**

http://tiny.cc/cdc-bmbl http://tiny.cc/canada-gov-psds

NIH Guidelines

https://www.cdc.gov/ http://tiny.cc/nih-bio-secure

Virginia Tech http://tiny.cc/vt-psds

